The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
Bone disease is a significant yet often underrecognized comorbidity in patients with systemic mastocytosis. Diagnosing and managing bone health in this patient population is challenging due to ...
Financial toxicity in cancer care: Experience from a tertiary care cancer center.
The National Academies of Sciences, Engineering, and Medicine Committee on Finding What Works in Health Care: Updating Standards for Systematic Reviews will hold an an open session webinar on May 13,.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results